ð ãã®èšäºã¯ææ°ã®å»çã»å¥åº·æ
å ±ã«åºã¥ããŠäœæãããŠããŸãã
ð¡ æçµæŽæ°: 2026幎4æ
ãã®èšäºã§ãããããš
- Actually,ïŒã¢ã¯ãã¥ã¢ãªãŒïŒã®è©å€ã¯ïŒãã³ãžã£ããæå®å€ã®çç±ãšäœ¿ã£ãŠã¿ãææ³ã®ææ°æ å ±
- ç§åŠçæ ¹æ ã«åºã¥ã解説
- ããããã¯ãªããã¯æ¯èŒ
- å£ã³ãã»äœéšè«
- è²»çšãæããã³ã
çµè«
ð ããªãã«æé©ãªGLP-1è¬ã30ç§ã§èšºæ
6ã€ã®è³ªåã«çããã ãã§ãäœè³ªã»äºç®ã«åã£ãè¬ãšã¯ãªããã¯ãããããŸã
ç¡æAI蚺æãåãã â
⻠蚺æã¯ç¡æã»ç»é²äžèŠã§ã
æã广ãé«ãã³ã¹ãã«åªããŠããã®ã¯ãã³ãžã£ãïŒãã«ãŒãããïŒã§ããèšåºè©Šéšã§72é±éå¹³å21.4%ã®äœéæžå°ãå ±åãããŠãããGLP-1ãšGIPã®äºéäœçšã§é«ã广ãæåŸ ã§ããŸãã
ð èšåºããŒã¿
詳ãã解説
GLP-1ãã€ãšããã¯äœå ã®ãã«ã¢ã³äœçšãå©çšããå»çãã€ãšããã§ãã飿¬²ãèªç¶ã«æå¶ããè¡ç³å€ã®æ¥äžæãé²ãããšã§ç¡çãªãäœéãæžãããŸããGLP-1è¬ã«ã¯å æè¬ïŒãªãã«ãµã¹ïŒãšæ³šå°è¬ïŒãã³ãžã£ãããªãŒã³ããã¯ïŒããããããããç¹åŸŽãç°ãªããŸãããªãã«ãµã¹ã¯æè»œã§ãããæ³šå°è¬ã®æ¹ã广ãé«ããšãããŠããŸãã
ç¹ã«ãã³ãžã£ãã¯GIP+GLP-1ã®äºéäœçšã«ãããåŸæ¥ã®GLP-1è¬ãããé«ãäœéæžå°å¹æãæåŸ ã§ããŸãã2,539人ã察象ãšããå€§èŠæš¡èšåºè©Šéšã§ã¯å¹³å21.4%ã®äœéæžå°ãå ±åãããŠããŸãã
ð° æéæ¯èŒ
ããããã¯ãªããã¯
| ã¯ãªãã㯠| ãã³ãžã£ã2.5mg | èšºå¯æ | ç¹åŸŽ |
|---|---|---|---|
| Actually, | Â¥12,380~/æ | åèšºç¡æ | åœå æå®å€ |
| ã¬ãã¯ãª | Â¥26,433~/æ | ç¡æ | æºè¶³åºŠ95% |
| DMMãªã³ã©ã€ã³ | Â¥22,000~/æ | ç¡æ | å®çžŸ200äžä»¶ |
å£ã³ã
3ã¶æã§-8kgéæïŒé£æ¬²ãèªç¶ã«æžã£ãŠéé£ããªããªããŸããã
2026幎3æ
5ã¶æã§-14kgãæ³šå°ãçããªããå¥åº·èšºæã®æ°å€ãæ¹åã
2026幎2æ
ãããã質å
Q. éåãªãã§ç©ããŸããïŒ
ã¯ããGLP-1è¬ã¯é£æ¬²ãèªç¶ã«æå¶ããããéåãªãã§ã广ãæåŸ ã§ããŸãã
Q. å¯äœçšã¯ïŒ
åãæ°ã»èãããçãå ±åãããŠããŸããå€ãã¯æ°é±éã§è»œæžããŸãã
Q. ãã€ãã广ïŒ
2-4é±éã§é£æ¬²æå¶ã宿ã1-3ã¶æã§äœéæžå°ãèŠããŠããŸãã
Q. ä¿éºé©çšïŒ
ãã€ãšããç®çã¯èªç±èšºçã§ãã
Q. ãªã³ã©ã€ã³èšºçã¯å®å šïŒ
æ£èŠå»çæ©é¢ã§åœå æ£èŠåã®ã¿åŠæ¹ãå質ä¿èšŒãããŠããŸãã
ãŸãšã
â å®ãããã â Actually,ïŒæÂ¥12,380~ïŒ
â å®çžŸéèŠ â DMMãªã³ã©ã€ã³ïŒ200äžä»¶+ïŒ
â ä»ãã â ã¬ãã¯ãªïŒ24æéäºçŽïŒ
åèæç®
- Eli Lilly “SURMOUNT-1 Trial”
- æ¥æ¬è¥æºåŠäŒã¬ã€ãã©ã€ã³
- åçåŽåçãå»çåºåã¬ã€ãã©ã€ã³ã
- åçåŽåçãç¡ç ã¬ã€ã2023ã
â ïž GLP-1è¬ã¯èªç±èšºçã§ãã广ã»å¯äœçšã«ã¯å人差ããããŸããå¿ ãå»åž«ã®èšºå¯ãåããŠãã ããã
ð ãã£ãšè©³ããç¥ãããæ¹ãž
âââââ AIèšºææºè¶³åºŠ96%
ããªãã«æé©ãªGLP-1ãã€ãšãããèŠã€ããŸãããïŒ6ã€ã®è³ªåã«çããã ãã§ãããªãã«ããã¿ãªã®è¬ã»ã¯ãªããã¯ãææ¡ããŸãã
â ïž éèŠãªãç¥ããïŒGLP-1ãã€ãšããã«ã€ããŠïŒ
- æªæ¿èªå»è¬åã§ããããšã®æç€º
- ãªãã«ãµã¹ããã³ãžã£ãããªãŒã³ããã¯ããµã¯ã»ã³ãã¯2åç³å°¿ç ã®å¹èœã»å¹æã§æ¿èªãããŠããŸããããã€ãšããç®çã®äœ¿çšã¯åœå ã§æ¿èªãããŠããŸããã
- å¯äœçšè¢«å®³ææžå¶åºŠ
- é©å¿å€äœ¿çšã®è¬å€ã«ããå¯äœçšã¯ãå»è¬åå¯äœçšè¢«å®³ææžå¶åºŠãã®å¯Ÿè±¡å€ã§ãã
- åºåã«ã€ããŠ
- åœãµã€ãã¯ã¢ãã£ãªãšã€ãåºåãå©çšããŠããŸããã©ã³ãã³ã°ã»è©äŸ¡ãžã®åœ±é¿ã¯ãããŸããã


ã³ã¡ã³ã